Edesa Biotech (EDSA) Liabilities and Shareholders Equity (2013 - 2026)

Edesa Biotech has reported Liabilities and Shareholders Equity for 13 years, with the latest figure at $14.7 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 253.26% year-over-year to $14.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $59.5 million (up 202.32% YoY) and the FY2025 annual result came in at $13.5 million, up 254.76% from the prior year.
• Liabilities and Shareholders Equity advanced to $14.7 million in Q4 2025 per EDSA's latest filing, from $13.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $24.0 million in Q1 2021 and troughed at $3.8 million in Q3 2024.
• A 5-year average of $12.3 million and a median of $12.0 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity tumbled 57.1% in 2024, then soared 254.76% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $12.3 million in 2021, then dropped by 5.42% to $11.7 million in 2022, then sank by 32.92% to $7.8 million in 2023, then tumbled by 46.83% to $4.2 million in 2024, then surged by 253.26% to $14.7 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $14.7 million, $13.5 million, and $14.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.